You are here: Home > Blogs
Company

The diabetes battle: Will Novo’s oral GLP-1 knock Trulicity off its perch?

  • December, 11 2018
  • 1855

Timing is of the essence for Novo Nordisk. The Danish company may use its priority review voucher to accelerate oral GLP-1 agonist candidate, semaglutide, past the regulators – though a decision is not confirmed. Buying a few more weeks – or months – to e

Company

Bayer Cuts Internal R&D, Looking Outside

  • December, 11 2018
  • 1476

Bayer’s late November announcement of 12,000 job cuts and a focus on ‘collaborative research models’ and ‘external innovations’ to fuel pharma R&D is not a surprise. Rumors had been swirling for months in the German press. Bayer board member and innov

Related Videos
Oliver Spray Analyst
Oliver Spray Analyst

M&A Outlook for 2018

Amanda Mucklus Analyst
Amanda Mucklus Analyst

Diversification Strategy

Pharma Intelligence
Pharma Intelligence

Biosimilars Battlegrounds

Pharma Intelligence
Pharma Intelligence

Q4 2018 Outlook Webinar

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back